Brachytherapy
Volume 8, Issue 1 , Pages 34-39 , January 2009

Analysis of the Pro-Qura Database: Rectal dose, implant quality, and brachytherapist's experience

  • Christopher R. Loiselle

      Affiliations

    • Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA
    • ,
  • Musaddiq Waheed

      Affiliations

    • Schiffler Cancer Center, Wheeling Jesuit University, Wheeling, WV
    • ,
  • John Sylvester

      Affiliations

    • Seattle Prostate Institute, Seattle, WA
    • ,
  • Zachariah A. Allen

      Affiliations

    • Schiffler Cancer Center, Wheeling Jesuit University, Wheeling, WV
    • ,
  • Peter D. Grimm

      Affiliations

    • Seattle Prostate Institute, Seattle, WA
    • ,
  • Steven Eulau

      Affiliations

    • Seattle Prostate Institute, Seattle, WA
    • ,
  • Wayne M. Butler

      Affiliations

    • Schiffler Cancer Center, Wheeling Jesuit University, Wheeling, WV
    • ,
  • Gregory S. Merrick

      Affiliations

    • Schiffler Cancer Center, Wheeling Jesuit University, Wheeling, WV
    • Corresponding Author InformationCorresponding author. Gregory S. Merrick, MD, Schiffler Cancer Center, Wheeling Hospital, 1 Medical Park, Wheeling, WV 26003-6300. Tel.: +1-304-243-3490; fax: +1-304-243-5047.

Received 22 May 2008 ,Revised 18 August 2008 ,Accepted 9 September 2008.

References 

  1. Cooperberg MR, Lubeck DP, Meng MV, et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141–2149
  2. Merrick GS, Wallner KE, Butler WM. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. J Urol. 2003;169:1643–1652
  3. Papagikos MA, Deguzman AF, Rossi PJ, et al. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)?. Brachytherapy. 2005;4:252–258
  4. Stock RG, Stone NN, Cesaretti JA, et al. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys. 2006;64:527–533
  5. Merrick GS, Wallner KE, Butler WM, et al. Brachytherapy in men aged ≤54 years with clinically localized prostate cancer. BJU Int. 2006;98:324–328
  6. Orio P, Wallner K, Merrick G, et al. Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation. Int J Radiat Oncol Biol Phys. 2007;67:342–346
  7. Merrick GS, Butler WM. Modified uniform seed loading for prostate brachytherapy: rationale, design, and evaluation. Tech Urol. 2000;6:78–84
  8. Blasko JC, Ragde H, Grimm PD. Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. Scand J Urol Nephrol Suppl. 1991;137:113–118
  9. Merrick GS, Butler WM, Wallner KE, et al. Long-term rectal function after permanent prostate brachytherapy. Cancer J. 2007;13:95–104
  10. Elliott K, Wallner K, Merrick G, et al. Medical malpractice of prostate brachytherapy. Brachytherapy. 2004;3:231–236
  11. Gelblum DY, Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2000;48:119–124
  12. Merrick GS, Butler WM, Dorsey AT, et al. Rectal function following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000;48:667–674
  13. Merrick GS, Butler WM, Dorsey AT, et al. Rectal dosimetric analysis following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1999;43:1021–1027
  14. Snyder KM, Stock RG, Hong SM, et al. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys. 2001;50:335–341
  15. Tran A, Wallner K, Merrick G, et al. Rectal fistulas after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005;63:150–154
  16. Marguet C, Raj GV, Brashears JH, et al. Rectourethral fistula after combination radiotherapy for prostate cancer. Urology. 2007;69:898–901
  17. Bishoff JT, Motley G, Optenberg SA, et al. Incidence of fecal and urinary incontinence following radical perineal and retropubic prostatectomy in a national population. J Urol. 1998;160:454–458
  18. Shekarriz B, Upadhyay J, Wood DP. Intraoperative, perioperative, and long-term complications of radical prostatectomy. Urol Clin North Am. 2001;28:639–653
  19. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001;166:876–881
  20. Herstein A, Wallner K, Merrick G, et al. I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial. Cancer J. 2005;11:385–389
  21. Waterman FM, Dicker AP. Effect of post-implant edema on the rectal dose in prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1999;45:571–576
  22. Taussky D, Yeung I, Wililams T, et al. Rectal-wall dose dependence on postplan timing after permanent-seed prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;54:358–363
  23. Merrick GS, Grimm PD, Sylvester J, et al. Initial analysis of Pro-Qura: a multi-institutional database of prostate brachytherapy dosimetry. Brachytherapy. 2007;6:9–15
  24. Wallner K, Roy J, Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1995;32:465–471
  25. Mayadev JS, Merrick G, Wallner K, et al. Dosimetric parameters of rectal toxicity and fistual formation after prostate brachytherapy. (Abstract) Int J Radiat Oncol Biol Phys. 2007;69:S313

PII: S1538-4721(08)00645-4

doi: 10.1016/j.brachy.2008.09.003

Brachytherapy
Volume 8, Issue 1 , Pages 34-39 , January 2009

Article Tools

* Image Usage & Resolution